Literature DB >> 1372967

Evidence of NK1 and NK2 tachykinin receptors and their involvement in histamine release in a murine mast cell line.

S A Krumins1, C A Broomfield.   

Abstract

Binding of [3H]substance P (SP) and histamine release were examined using a cloned mouse mast cell line. SP binding was saturable and specific. In the presence of 30 mM Na2SO4/50 mM Tris buffer, SP interacted with two types of binding sites with Kd values of 0.3 and 40 nM. High-affinity SP binding was blocked by the inclusion of 0.5 uM of the NK1 receptor selective ligand septide in the binding mixture. Neurokinin A (NKA) evoked concentration-dependent histamine release. At concentrations in the nanomolar range, the NK1 preferring agonists SP, SP methylester and physalaemin evoked less than or equal to 5% net release of histamine, which was substantially less than the maximum effect of NKA (+37%) in the micromolar range. Pretreatment of the cells with the NK2 antagonist peptide A reduced NKA-induced histamine release. [D-Arg1,D-Phe5,D-Trp7,9,Leu11]-substance P, a putative SP antagonist, also elicited histamine release in the micromolar range, apparently acting as an agonist at the NK2 site. Compound 48/80, N-terminal SP fragments, neurokinin B and the two selective NK2 receptor antagonists cyclo(Gln-Trp-Phe-(R)-[ANC-2]Leu-Met) (peptide A) and cyclo(Gln-Trp-Phe-Gly-Leu-Met) (peptide B) were ineffective. Although the results suggest the coexistence of functional NK1 and NK2 receptors, it appears that in this mast cell line neurokinin-induced histamine release is primarily mediated by the NK2 receptor, characterized biochemically as a low affinity binding site with a Kd value of 40 nM for SP.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1372967     DOI: 10.1016/0143-4179(92)90516-y

Source DB:  PubMed          Journal:  Neuropeptides        ISSN: 0143-4179            Impact factor:   3.286


  8 in total

1.  Role of substance P and calcitonin gene-related peptide in acid-induced augmentation of opossum esophageal blood flow.

Authors:  M J Feldman; G P Morris; W G Paterson
Journal:  Dig Dis Sci       Date:  2001-06       Impact factor: 3.199

2.  NK2 receptors mediate plasma extravasation in guinea-pig lower airways.

Authors:  C Tousignant; C C Chan; D Guevremont; C Brideau; J J Hale; M MacCoss; I W Rodger
Journal:  Br J Pharmacol       Date:  1993-02       Impact factor: 8.739

3.  Role of tachykinin NK2 receptors in normal and altered rectal sensitivity in rats.

Authors:  M Toulouse; A M Coelho; J Fioramonti; A Lecci; C Maggi; L Buéno
Journal:  Br J Pharmacol       Date:  2000-01       Impact factor: 8.739

4.  Mechanisms underlying the inhibitory effects of tachykinin receptor antagonists on eosinophil recruitment in an allergic pleurisy model in mice.

Authors:  Ana Leticia Alessandri; Vanessa Pinho; Danielle G Souza; Maria Salete de A Castro; Andre Klein; Mauro M Teixeira
Journal:  Br J Pharmacol       Date:  2003-11       Impact factor: 8.739

5.  Disodium cromoglycate inhibits capsaicin-induced eosinophil infiltration of conjunctiva independent of mast cells.

Authors:  Nobuyuki Ebihara; Motoaki Nishikawa; Akira Murakami
Journal:  Jpn J Ophthalmol       Date:  2006 May-Jun       Impact factor: 2.211

6.  Intravenous dexamethasone pretreatment reduces remifentanil induced cough.

Authors:  Mi-Suk Yu; Ji Yeon Kim; Hye Young Kim
Journal:  Korean J Anesthesiol       Date:  2011-06-17

7.  Prostaglandin D2-supplemented "functional eicosanoid testing and typing" assay with peripheral blood leukocytes as a new tool in the diagnosis of systemic mast cell activation disease: an explorative diagnostic study.

Authors:  Dirk Schäfer; Peter Dreßen; Stefan Brettner; Norbert-Folke Rath; Gerhard J Molderings; Katrin Jensen; Christina Ziemann
Journal:  J Transl Med       Date:  2014-08-12       Impact factor: 5.531

8.  A comparison of the effect of pretreatment with intravenous dexamethasone, intravenous ketamine, and their combination, for suppression of remifentanil-induced cough: A randomized, double-blind, placebo-controlled clinical trial.

Authors:  Azim Honarmand; Mohammadreza Safavi; Farnaz Khalighinejad
Journal:  Adv Biomed Res       Date:  2013-07-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.